Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131037 · ClinicalTrials.gov registry record · Phase 1
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Candel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03131037 is a Phase 1 study that has completed, run by Candel Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03131037, a Phase 1 study, has completed, sponsored by Candel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase I dose escalation study of CAN-2409 plus prodrug in patients with non-small cell lung cancer (NSCLC). The primary clinical objective of the study is to evaluate the safety of CAN-2409 plus prodrug when combined with standard surgery for NSCLC. The primary scientific objective is to determine the immunologic changes induced by CAN-2409 plus prodrug.
Interventions
- BIOLOGICAL CAN-2409 + valacyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2023-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03131037
The ClinicalTrials.gov registry entry for NCT03131037 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAN-2409 + valacyclovir is the first listed.
NCT03131037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03131037 about?
NCT03131037 is a clinical study titled "Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer". This is a phase I dose escalation study of CAN-2409 plus prodrug in patients with non-small cell lung cancer (NSCLC). The primary clinical objective of the study is to evaluate the safety of CAN-2409 plus prodrug when combined with standard surgery for NSCLC. The primary scientific objective is to d...
What is the current status of trial NCT03131037?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-05-04. Estimated completion is 2023-09-20.
What interventions are being tested in trial NCT03131037?
The interventions under investigation include: CAN-2409 + valacyclovir (BIOLOGICAL).
Who is sponsoring clinical trial NCT03131037?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.